Apollomics Inc.

Maxpro Capital Acquisition Corp. (Nasdaq: JMAC), sponsored by Maxpro Capital, completed its initial public offering in 2021 with a focus on the healthcare and biopharmaceutical sectors. In September 2022, the blank-check company announced a definitive business combination with Apollomics Inc., a clinical-stage biopharmaceutical company developing targeted oncology therapies. The transaction closed in 2023, bringing Apollomics to public markets through the de-SPAC process, with the combined company listing on Nasdaq under the ticker APLM. Apollomics concentrates its pipeline on novel treatments for solid tumors and hematologic cancers. The deal is now closed. Sign up at SpacDesk for full data and analytics on JMAC and hundreds of other SPAC transactions.

SPAC Counterparty (1)